プロモーションスケジュール H. Lundbeck A/S
詳細なスケジュール
簡易グラフ
会社について H. Lundbeck A/S
H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia. さらに詳しくIndustry | Pharmaceuticals |
---|---|
Sector | Health Care |
Валюта | usd |
Валюта отчета | usd |
Див.доход ао | 16.83 |
Дивиденд ао | 0.7 |
Сайт | https://www.lundbeck.com |
Цена ао | 4.43 |
1日あたりの価格変動: | 0% (4.43) |
---|---|
週ごとの価格変動: | 0% (4.43) |
月ごとの料金変更: | 0% (4.43) |
3ヶ月間の価格変動: | -15.09% (5.2175) |
半年間の価格変動: | -27.38% (6.1) |
年間の価格変動: | +3.87% (4.265) |
3年間の価格推移: | 0% (4.43) |
5年間の価格推移: | 0% (4.43) |
10年間の価格推移: | 0% (4.43) |
年初からの価格変動: | -15.62% (5.25) |
|
過小評価
|
効率
|
|||||||||||||||||||||||||||||||||||||
配当金
|
義務
|
成長の衝動
|
機関 | 音量 | 共有, % |
---|---|---|
Vanguard International Stock Index-Total Intl Stock Indx | 766645 | 0.38 |
Vanguard Tax Managed Fund-Vanguard Developed Markets Index Fund | 448123 | 0.23 |
iShares Core MSCI EAFE ETF | 373578 | 0.19 |
DFA International Small Cap Value Portfolio | 233923 | 0.12 |
iShares MSCI EAFE Small Cap ETF | 208316 | 0.1 |
Vanguard Intl Equity Index Fds-FTSE All World ex U.S. Index Fund | 124308 | 0.06 |
Vanguard International Stock Index-Vanguard European Stock Index | 124066 | 0.06 |
iShares Core MSCI Total International Stock ETF | 96483 | 0.05 |
Dimensional ETF Tr-Dimensional International Small Cap Value ETF | 80813 | 0.04 |
iShares MSCI Denmark ETF | 77939 | 0.04 |
スーパーバイザー | 役職 | 支払い | 生年 |
---|---|---|---|
Mr. Joerg Hornstein | CFO & Executive VP of Corporate Functions | 1.23M | 1977 (48 年) |
Mr. Lars Bang | Executive Vice President of Product Development & Supply | 1.14M | 1962 (63 年) |
Dr. Per Johan Luthman | Executive Vice President of Research & Development | 1.27M | 1959 (66 年) |
Mr. Charl van Zyl | President & CEO | 5.34M | 1967 (58 年) |
Dr. Tarek Samad Ph.D. | Senior VP & Head of Research | N/A | |
Mr. Palle Holm Olesen | Chief Specialist & VP of Investor Relations | N/A | |
Mr. Ole Chrintz | Senior Vice President of International Markets | N/A | 1958 (67 年) |
Dr. Rupert Sandbrink M.D., Ph.D. | Senior VP & Head of Clinical Development | N/A | 1964 (61 年) |
Ms. Tine Ostergaard Hansen | Senior Vice President of Corporate Communications & Public Affairs | N/A | 1975 (50 年) |
Ms. Dianne Holto | Executive Vice President of People & Culture | 1973 (52 年) |